{"id":"NCT00813995","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)","officialTitle":"A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12-09","primaryCompletion":"2010-08-09","completion":"2010-08-09","firstPosted":"2008-12-23","resultsPosted":"2011-09-13","lastUpdate":"2017-05-12"},"enrollment":395,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Comparator: Sitagliptin phosphate","otherNames":["GLUCOPHAGE®"]},{"type":"DRUG","name":"Comparator: Placebo","otherNames":["GLUCOPHAGE®"]}],"arms":[{"label":"Sitagliptin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A study to assess the safety and efficacy of the addition of sitagliptin compared to placebo in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (A1C) at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Sitagliptin","deltaMin":-1.02,"sd":0.99},{"arm":"Placebo","deltaMin":-0.14,"sd":1.22}],"pValues":[{"comp":"OG000 vs OG001","p":"<.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22672586"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":197},"commonTop":["UPPER RESPIRATORY TRACT INFECTION"]}}